查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1676942

全球放射栓塞市场按成分、治疗类别、肿瘤类型、应用程式和最终用户划分 - 预测 2025-2030 年

Radioembolization Therapy Market by Component, Treatment Category, Tumor Type, Application Procedure, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计放射栓塞市场在 2024 年的价值将达到 10.9 亿美元，在 2025 年达到 11.5 亿美元，并以 5.90% 的复合年增长率增长，到 2030 年达到 15.4 亿美元。

主要市场统计数据
基准年 2024 年 10.9亿美元
预计 2025 年 11.5亿美元
预测年份 2030 15.4亿美元
复合年增长率（%） 5.90％

放射栓塞疗法已成为肝癌治疗的革命性解决方案，为常规治疗方法常常失败的情况带来了希望。本执行摘要探讨了先进医疗技术与危重患者照护交叉市场的复杂细节。随着技术创新的快速发展和对标靶治疗的日益关注，本分析将说明这一变革领域的当前趋势、新出现的挑战和机会。

近年来，医疗相关人员和研究人员对放射栓塞疗法的兴趣日益浓厚，因为它是一种微创治疗方法，可以高精度地瞄准肝臟肿瘤，同时减少对健康组织的附带损害。这种受控的内部照射不仅凸显了个人化在癌症治疗中的重要性，而且重新定义了对抗原发性及转移性肝癌的治疗标准。这里提供的策略见解旨在为决策者、医疗保健创新者和行业领导者提供当前市场动态、关键成长要素和需要进一步创新的领域的全面概述。

透过彻底检视临床应用、技术进步和主要产业参与者的影响，它旨在提出蓝图来支援即时的战术性转变和长期策略规划。该报告以平衡的观点融合了临床证据和市场资料分析，成为相关人员在复杂的放射栓塞领域的重要指南。

推动现代放射栓塞治疗的变革

近年来，放射栓塞的情况发生了显着变化。技术创新和对肿瘤生物学和放射物理学的进一步了解导致了治疗策略的模式转移。这一演变突出了先进成像技术、精确设计的输送系统和新型放射性微球的集成，旨在比以往更有效地输送目标剂量。

导管设计的进步提高了注射过程的精确度和安全性，进一步提高了放射栓塞治疗的治疗指数。除了这些技术改进之外，还采用了成像方式来增强治疗计划和即时监测，从而提高临床可靠性。此外，不同地区不断发展的法律规范和报销政策也为更广泛地获取和接受这些创新治疗方法铺平了道路。

医生、工程师和医疗设备製造商之间加强合作也加快了创新的脚步。相关人员现在可以利用临床专业知识和技术力的协同效应，从而提高放射栓塞治疗的整体效果。对个人化治疗方法的关注正在使市场从一刀切的方式转向更客製化、精准化的方式，进一步巩固其在现代肿瘤治疗中的作用。

这趟转型之旅并非一帆风顺。将新技术融入传统医疗保健框架需要对从业人员进行大量的培训和重新调整通讯协定。儘管如此，改善患者治疗效果和降低全身毒性等潜在益处推动着该领域治疗策略的持续发展。

揭示市场动态的细分洞察

为了更深入了解放射栓塞市场，有必要对几个关键部分进行精确分析。市场依组件分析进行剖析，包括导管、核子医学设备、放射性微球和X光设备等先进设备。这种细分有助于了解每个组件如何在促进无缝治疗过程中发挥关键作用，并确保技术符合安全标准和业务效率。

此外，也透过治疗类别的角度对市场进行分析，区分治疗方法和安宁疗护方法。这种差异突显了放射栓塞的双重性质：一些患者寻求根治性治疗以根除疾病，而另一些患者面对难治性疾病，选择旨在改善生活品质的安宁疗护。这种双重性激发了製造商的创新，寻求平衡临床效果和以患者为中心的结果。

此外，透过细分肿瘤类型，可分为转移性肝癌和原发性肝癌。这种区别至关重要，因为转移性肝癌的生物学特征和进展模式通常需要与原发性肝恶性肿瘤不同的治疗考虑。因此，这种细分不仅可以提供治疗方案，还可以引导研发力量转向专门的标靶治疗。

根据应用技术的分割透过区分肝臟肿瘤、肝叶治疗和肝节段治疗进一步提高了我们的理解。每种技术都提供了独特的方法来解决肿瘤形态和患者解剖结构的细微差异，从而满足个体的临床需求。最后，按最终用户进行细分有助于描绘出各种医疗保健服务环境的状况。最终用户的多样性，从门诊手术中心和癌症研究机构到综合医院，显示放射栓塞技术的广泛应用，并凸显了市场的广泛范围和适应性。

目录

第 1 章 简介

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 全球肝癌和肝硬化发生率不断上升
      • 扩大全球医疗基础设施
      • 全球各国政府对癌症治疗的支持与资助
    • 限制因素
      • 放射栓塞治疗费用高昂
    • 机会
      • 医院与生技公司进行策略合作，创新新治疗方法
      • 开发替代放射性同位素以降低生产成本并提高可近性
    • 任务
      • 放射栓塞治疗的监管核准和报销问题复杂
  • 市场区隔分析
    • 治疗类别：放射栓塞治疗越来越偏好
    • 应用流程：放射栓塞治疗在肝肿瘤治疗的拓展应用
  • 波特五力分析
  • PESTEL 分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

6. 放射栓塞术市场（按组件）

  • 导管
  • 核子医学设备
  • 放射性微球
  • X光设备

7. 放射栓塞治疗市场（依治疗类别）

  • 治疗
  • 宽慰

8. 放射栓塞市场（依肿瘤类型）

  • 转移性肝癌
  • 原发性肝癌

第九章放射栓塞市场申请程序

  • 肝臟肿瘤
  • 叶治疗
  • 分段治疗

第 10 章 放射栓塞市场（依最终使用者划分）

  • 门诊手术中心
  • 癌症研究所
  • 医院

第 11 章美洲放射栓塞市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

12. 亚太地区放射栓塞市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

13. 欧洲、中东和非洲放射栓塞市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十四章 竞争格局

  • 2024 年市场占有率分析
  • FPNV 定位矩阵，2024 年
  • 竞争情境分析
  • 战略分析与建议

公司列表

  • Bayer AG
  • Becton Dickinson & Company
  • Boston Scientific Corporation
  • Cook Medical
  • Elekta AB
  • Fortis Healthcare Limited
  • Hamilton Health Sciences
  • Mayo Clinic Health System
  • Merit Medical Systems, Inc.
  • Nordion Inc.
  • Northwestern Memorial HealthCare.
  • Radiological Society of North America, Inc.
  • Siemens AG
  • Sirtex Medical Pty Ltd
  • Stryker Corporation
  • Terumo Corporation
  • United HealthCare Services, Inc
Product Code: MRR-562E923A9568

The Radioembolization Therapy Market was valued at USD 1.09 billion in 2024 and is projected to grow to USD 1.15 billion in 2025, with a CAGR of 5.90%, reaching USD 1.54 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 1.09 billion
Estimated Year [2025] USD 1.15 billion
Forecast Year [2030] USD 1.54 billion
CAGR (%) 5.90%

Radioembolization therapy has emerged as a groundbreaking solution in the treatment landscape for liver cancers, offering hope where conventional treatments have often fallen short. This executive summary explores the intricate details of a market that stands at the convergence of advanced medical technology and critical patient care. In an era of rapidly evolving innovations and intensified focus on targeted oncological therapies, our analysis encapsulates current trends, emerging challenges, and opportunities in this transformative field.

In recent years, medical professionals and researchers have increasingly turned to radioembolization as a minimally invasive procedure that targets liver tumors with high precision, thereby reducing collateral damage to healthy tissues. This controlled form of internal radiation not only underscores the significance of personalization in cancer treatment but also redefines standards of care in the fight against both primary and metastatic liver cancers. The strategic insights provided here are designed to offer decision-makers, healthcare innovators, and industry leaders a comprehensive overview of the current market dynamics, key growth drivers, and areas ripe for further innovation.

Through an in-depth exploration of clinical applications, technological advancements, and the influence of pivotal industry players, we aim to present a roadmap that supports both immediate tactical shifts and long-term strategic planning. With a balanced perspective that merges clinical evidence with market data analysis, this report serves as an essential guide for stakeholders seeking to navigate the complexities of the radioembolization therapy space.

Transformative Shifts Driving the Modern Radioembolization Therapy Landscape

The landscape of radioembolization therapy has undergone significant transformations in recent years. Technological innovations, coupled with an increased understanding of tumor biology and radiation physics, have catalyzed a paradigm shift in treatment strategies. This evolution is underscored by the integration of advanced imaging technologies, precision-engineered delivery systems, and novel radioactive microspheres designed to deliver targeted doses more effectively than ever before.

Advancements in catheter design have improved the precision and safety of the infusion process, further boosting the therapeutic index of radioembolization treatments. Complementary to these technical improvements is the adoption of imaging modalities that enhance treatment planning and real-time monitoring, thereby driving greater clinical confidence. Additionally, the evolving regulatory frameworks and reimbursement policies across various regions have paved the way for increased accessibility and acceptance of these innovative treatment procedures.

Increasing collaborations among physicians, engineers, and medical device manufacturers have also accelerated the pace of innovation. Stakeholders are now able to harness the synergy between clinical expertise and technological prowess, thereby enhancing the overall effectiveness of radioembolization procedures. With a focus on personalized treatment regimens, the market is shifting from a one-size-fits-all approach to a more customized, precision-based methodology, further solidifying its role in modern oncological care.

This transformative journey is not without challenges. The integration of new technologies into traditional healthcare frameworks requires extensive training and a recalibration of practitioner protocols. Nonetheless, the potential benefits in terms of improved patient outcomes and reduced systemic toxicities are driving the continuous evolution of therapeutic strategies in this space.

Segmentation Insights Illuminating Market Dynamics

A deeper understanding of the radioembolization therapy market emerges from a precise analysis of several key segmentation dimensions. The market is dissected based on component analysis, which includes sophisticated devices such as catheters, nuclear medicine equipment, radioactive microspheres, and x-ray equipment. This segmentation allows us to appreciate how each component plays a pivotal role in facilitating a seamless treatment process, where technology meets safety standards and operational efficiency.

Furthermore, the market is analyzed through the lens of treatment categories, distinguishing between curative and palliative approaches. Such differentiation underscores the dual nature of radioembolization therapy, where some patients seek radical treatment with the intent to eradicate the disease, while others opt for palliative care aimed at improving quality of life in the face of intractable conditions. This duality has spurred innovation as manufacturers strive to balance clinical efficacy with patient-centric outcomes.

In addition, tumor type segmentation provides an insightful breakdown into cases of metastatic liver cancer versus primary liver cancer. This distinction is crucial, as the biological characteristics and progression patterns of metastatic liver cancer often require different therapeutic considerations compared to primary liver malignancies. As a result, this segmentation not only informs treatment protocols but also directs research and development efforts toward specialized, targeted therapies.

The segmentation based on application procedure further refines our understanding by differentiating between liver tumor, lobar therapy, and segmental therapy. Each procedure offers a unique approach to addressing the nuances of tumor morphology and patient anatomy, thereby catering to individualized clinical needs. Finally, segmentation by end-user helps chart the landscape across various healthcare delivery settings. From ambulatory surgical centers and cancer research institutes to comprehensive hospitals, the diversity in end-users points to a broad-based adoption of radioembolization therapy techniques, accentuating the market's expansive reach and adaptability.

Based on Component, market is studied across Catheters, Nuclear Medicine Equipment, Radioactive Microspheres, and X-Ray Equipment.

Based on Treatment Category, market is studied across Curative and Palliative.

Based on Tumor Type, market is studied across Metastatic Liver Cancer and Primary Liver Cancer.

Based on Application Procedure, market is studied across Liver Tumour, Lobar Therapy, and Segmental Therapy.

Based on End-User, market is studied across Ambulatory Surgical Centers, Cancer Research Institutes, and Hospitals.

Regional Insights Highlighting Global Trends

The global footprint of radioembolization therapy is marked by distinct regional trends that reflect varying degrees of market maturity and healthcare infrastructure readiness. In the Americas, robust healthcare systems and substantial investments in oncological research have supported the early adoption and integration of radioembolization therapy. Clinicians and healthcare providers in this region are leveraging advanced technologies to push the boundaries of personalized medicine.

Across Europe, the Middle East, and Africa, regulatory dynamics, coupled with a balanced emphasis on both innovative research and cost-effective care solutions, are shaping the market landscape. European nations, in particular, have seen a rapid acceleration in clinical research alongside an emphasis on safety protocols and treatment efficacy. Meanwhile, emerging markets within the Middle East and Africa are gradually building capacity, laying the groundwork for a more extensive uptake of these advanced therapeutic solutions.

In the Asia-Pacific region, rapid economic growth, government initiatives, and strategic partnerships are driving significant investments in healthcare innovation. The region is witnessing a swift expansion in infrastructural capabilities and a surge in clinical trials, underpinning a growing interest in adopting radioembolization therapy at scale. The confluence of progressive health policies and increased public awareness ensures that radioembolization therapy will continue to play a central role in addressing the rising cancer burden in these territories.

These regional insights not only highlight the market's diversity but also serve as a catalyst for cross-regional knowledge sharing and strategic collaborations. The global nature of the market is driving a convergence of best practices that benefit all stakeholders and ultimately lead to enhanced patient care worldwide.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

In-Depth Company Insights Shaping the Market Evolution

At the core of radioembolization therapy's innovation and growth are the key companies that continuously push the envelope of medical technology. Industry leaders such as Bayer AG, Becton Dickinson & Company, Boston Scientific Corporation, and Cook Medical are at the forefront of research and development, leveraging vast resources to innovate new solutions for precise treatment delivery. This competitive landscape is further enriched by players like Elekta AB, Fortis Healthcare Limited, and Hamilton Health Sciences, whose contributions highlight the integration of clinical expertise with innovative technological advancements.

Innovative healthcare institutions including the Mayo Clinic Health System, Merit Medical Systems, Inc., Nordion Inc., and Northwestern Memorial HealthCare are driving clinical excellence and setting high benchmarks in therapeutic efficacy. Furthermore, the Radiological Society of North America, Inc. plays a crucial role in fostering educational initiatives and promoting research collaborations, while global giants such as Siemens AG and Sirtex Medical Pty Ltd are pivotal in optimizing treatment dosimetry and procedural accuracy.

Other influential entities such as Stryker Corporation, Terumo Corporation, and United HealthCare Services, Inc. enrich the competitive environment by focusing on process innovation, patient safety measures, and cost containment strategies. The collaboration and competition among these companies not only drive technological progress but also enhance the overall standards of care, ensuring that patients receive the most advanced and effective treatments available.

Each of these industry leaders contributes unique insights based on their regional dominance, product portfolios, and research trajectories. Their continued innovation is instrumental in addressing the evolving needs of the radioembolization therapy market, ensuring a trajectory of sustained growth and improved patient outcomes.

The report delves into recent significant developments in the Radioembolization Therapy Market, highlighting leading vendors and their innovative profiles. These include Bayer AG, Becton Dickinson & Company, Boston Scientific Corporation, Cook Medical, Elekta AB, Fortis Healthcare Limited, Hamilton Health Sciences, Mayo Clinic Health System, Merit Medical Systems, Inc., Nordion Inc., Northwestern Memorial HealthCare., Radiological Society of North America, Inc., Siemens AG, Sirtex Medical Pty Ltd, Stryker Corporation, Terumo Corporation, and United HealthCare Services, Inc. Actionable Strategic Recommendations for Industry Leaders

Industry leaders can capitalize on emerging opportunities in the radioembolization therapy market by embracing a multi-faceted approach that aligns with both current trends and future advancements. First, investing in research and innovation remains paramount. As technology continues to evolve, allocating resources towards the development of next-generation delivery systems and enhanced imaging modalities will be critical. Leaders should focus on partnerships with research institutions and clinical experts to foster an environment of collaborative innovation that accelerates the translation of laboratory breakthroughs to clinical application.

Second, market penetration and global outreach should be driven by a deep understanding of regional dynamics. Customizing product offerings to meet the specific clinical and regulatory requirements of diverse markets will improve adoption rates. This involves tailoring devices and protocols for varied healthcare settings, which range from advanced hospitals to emerging cancer research centers. A data-driven approach to regional market analysis can guide strategic investment and inform the development of localized training programs, ensuring that new technologies are efficiently integrated into current clinical practices.

Third, enhancing patient-centric strategies through personalized therapy protocols can provide a competitive edge. By leveraging segmentation insights based on treatment category, tumor type, and application procedures, companies can align their product development efforts with real-world patient needs. This strategy not only improves treatment outcomes but also builds greater trust and recognition among both clinicians and patients.

Moreover, forging strategic alliances across the value chain-including partnerships with technology providers, regulatory advisors, and healthcare institutions-can drive synergies that accelerate market growth. Through collaborative ventures, companies can share best practices, streamline manufacturing processes, and overcome common regulatory hurdles.

Lastly, adopting proactive communication strategies to educate clinicians, patients, and regulatory bodies will be crucial for market expansion. An informed market is more likely to embrace innovative therapeutic solutions, thereby creating a favorable ecosystem for sustained growth. Effective educational campaigns and stakeholder engagement initiatives should form an integral part of any company's strategy moving forward.

By implementing these actionable recommendations, industry leaders can not only enhance their competitive positioning but also drive meaningful advancements in clinical practice, ultimately improving the standard of care for patients worldwide.

Conclusion: Summarizing the Key Insights

In summary, the evolving landscape of radioembolization therapy is marked by significant technological advances, regional diversification, and complex market dynamics that necessitate adaptive strategies by industry stakeholders. Our analysis underscores the importance of an integrated approach that leverages both technological innovation and strategic collaborations to meet the rising demand for personalized cancer treatments.

From understanding the nuances of market segmentation based on component, treatment category, tumor type, application procedure, and end-users to appreciating the subtle regional influences across the Americas, Europe, Middle East & Africa, and Asia-Pacific, it is evident that a one-size-fits-all strategy is ineffective in this complex domain. The diverse contributions of key companies reaffirm the need for continuous innovation and strategic investments that align product offerings with clinical requirements. These insights serve as a roadmap for how to navigate the challenges and opportunities in a market that is not only competitive but is also rapidly evolving.

As the radioembolization therapy landscape continues to mature, ensuring that research, innovation, and regional insights are adequately integrated into strategic planning will be essential. This integrated approach will support better clinical outcomes and drive sustained market growth, ensuring that cutting-edge treatments are accessible to patients globally.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of liver cancer and cirrhosis among patients globally
      • 5.1.1.2. Expansion in healthcare infrastructure worldwide
      • 5.1.1.3. Government support and funding for cancer treatment initiatives worldwide
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with radioembolization procedures
    • 5.1.3. Opportunities
      • 5.1.3.1. Strategic partnerships between hospitals and biotechnology firms for innovating novel therapies
      • 5.1.3.2. Development of alternative radioisotopes for lowering production costs and increasing accessibility
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulatory approvals and reimbursement issues for radioembolization therapy
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Category: Increasing preference for curative treatments in radioembolization therapy
    • 5.2.2. Application Procedure: Expanding application of radioembolization therapy liver tumor treatments
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Radioembolization Therapy Market, by Component

  • 6.1. Introduction
  • 6.2. Catheters
  • 6.3. Nuclear Medicine Equipment
  • 6.4. Radioactive Microspheres
  • 6.5. X-Ray Equipment

7. Radioembolization Therapy Market, by Treatment Category

  • 7.1. Introduction
  • 7.2. Curative
  • 7.3. Palliative

8. Radioembolization Therapy Market, by Tumor Type

  • 8.1. Introduction
  • 8.2. Metastatic Liver Cancer
  • 8.3. Primary Liver Cancer

9. Radioembolization Therapy Market, by Application Procedure

  • 9.1. Introduction
  • 9.2. Liver Tumour
  • 9.3. Lobar Therapy
  • 9.4. Segmental Therapy

10. Radioembolization Therapy Market, by End-User

  • 10.1. Introduction
  • 10.2. Ambulatory Surgical Centers
  • 10.3. Cancer Research Institutes
  • 10.4. Hospitals

11. Americas Radioembolization Therapy Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Radioembolization Therapy Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Radioembolization Therapy Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. SINTX Technologies partners with NED Medical under a joint development agreement
    • 14.3.2. ABK Biomedical received FDA approval to proceed to Stage 2 of their Route90 pivotal study,
    • 14.3.3. Juravinski Hospital and Cancer Centre introduced radioembolization to treat liver cancer
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Bayer AG
  • 2. Becton Dickinson & Company
  • 3. Boston Scientific Corporation
  • 4. Cook Medical
  • 5. Elekta AB
  • 6. Fortis Healthcare Limited
  • 7. Hamilton Health Sciences
  • 8. Mayo Clinic Health System
  • 9. Merit Medical Systems, Inc.
  • 10. Nordion Inc.
  • 11. Northwestern Memorial HealthCare.
  • 12. Radiological Society of North America, Inc.
  • 13. Siemens AG
  • 14. Sirtex Medical Pty Ltd
  • 15. Stryker Corporation
  • 16. Terumo Corporation
  • 17. United HealthCare Services, Inc

LIST OF FIGURES

  • FIGURE 1. RADIOEMBOLIZATION THERAPY MARKET MULTI-CURRENCY
  • FIGURE 2. RADIOEMBOLIZATION THERAPY MARKET MULTI-LANGUAGE
  • FIGURE 3. RADIOEMBOLIZATION THERAPY MARKET RESEARCH PROCESS
  • FIGURE 4. RADIOEMBOLIZATION THERAPY MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 21. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. RADIOEMBOLIZATION THERAPY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 27. RADIOEMBOLIZATION THERAPY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. RADIOEMBOLIZATION THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. RADIOEMBOLIZATION THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY CATHETERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY NUCLEAR MEDICINE EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY RADIOACTIVE MICROSPHERES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY X-RAY EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY CURATIVE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY PALLIATIVE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY METASTATIC LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY PRIMARY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY LIVER TUMOUR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY LOBAR THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY SEGMENTAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 235. RADIOEMBOLIZATION THERAPY MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 236. RADIOEMBOLIZATION THERAPY MARKET, FPNV POSITIONING MATRIX, 2024